Global Opportunities in Neurostimulation Technologies Targeting Neurological Conditions
Published January 2020 | 114 Pages | 33 Exhibits | Forecasts Through 2024
Order individually or subscribe and get a complete intel platform.
Overview
Global sales of neurostimulation technologies targeting neurological disorders were estimated at more than $1.5 billion in 2019. Among these, deep brain stimulation (DBS) for Parkinson's and Essential Tremor contribute the largest share of sales (56%) based on the relatively established nature of this application and the high cost of the implants. It is followed by DRE (29% of sales), which is also dominated by expensive implants. In contrast, neurostimulation-based treatment of MDD and post-stroke extremity motor dysfunction are served primarily by noninvasive technologies. The former is a more recent application that is expected to continue its reliance on noninvasive technologies, whereas the latter is a more traditional user of noninvasive technologies that may be augmented with implant therapy late in the forecast period.
Looking at the market from the standpoint of geography, the U.S. clearly dominates sales based on its expansive use of expensive implants. However, its 74% share of global sales in 2019 is projected to decline slightly to 71% in 2024 as other nations expand their use of implants and as noninvasive technologies find increasing global acceptance. Overall, the composite global market is projected to increase at a 12.7% real annual rate to $2.75 billion in 2024.
For a detailed analysis of this market, become a Medtch Pro subscriber or purchase access to this single report.
Companies Covered
Abbott/St. Jude Medical
Adept Neuro SA
Aleva Neurotherapeutics
Bioness
Bionic Enterprises
Boston Scientific
Cala Health
Cerbomed
CerebralRx
Cervel Neurotech
Clinatec
CorTec/Wyss Center
CVRx
DARPA ElectRx
Deep Brain Innovations
Finetech Medical
Functional Neuromodulation
Hanger
LivaNova
Medtronic
MicroTransponder
Neuronetics
Neuronix
NeuroPace
NeuroSigma
Nexeon Medsystems
Ottobock
PINS Medical
SceneRay
Tal Medical
Table of Contents
Executive Summary
Targeted Neurological Conditions
Neurostimulation Technologies Targeting Neurological Disorders
Product Markets
Supplier Shares
Summary Exhibit 1: Overview of Selected Neurological Conditions Currently Amenable to Neurostimulation Therapy
Summary Exhibit 2: Current and Emerging Neurostimulation Technologies Targeting Neurological Conditions
Summary Exhibit 3: Global Market for Neurostimulation Technologies Targeting Neurological Disorders by Major Type, Clinical Application and Major Geography, 2018 - 2024
Summary Exhibit 4: Neurostimulation Technologies Targeting Neurological Conditions, Estimated Global Supplier Shares, 2018
1. Targeted Neurological Conditions
1.1 Refractory Epilepsy
1.2 Chronic Depression
1.3 Ischemic Stroke
1.4 Neurodegenerative Disorders
1.4.1 Parkinson's Disease
1.4.2 Essential Tremor
1.4.3 Alzheimers
1.5 Post-Traumatic Stress Disorder
1.6 Migraine
1.7 Cluster Headache
Exhibit 1-1: Overview of Selected Neurological Conditions Currently Amenable to Neurostimulation Therapy
Exhibit 1-2: Distribution of Depression by Geography, Age and Sex, 2015
Exhibit 1-3: Current and Forecast Prevalence of Alzheimer's, 2015-2050
2. Neurostimulation Technologies Targeting Neurological Conditions
2.1 Drug Refractory Epilepsy
2.1.1 Bionic Enterprises
2.1.2 Cerbomed/tVNS
2.1.3 CerebralRX
2.1.4 LivaNova
2.1.5 NeuroPace
2.1.6 NeuroSigma
2.1.7 PINS Medical
2.2 Major Depressive Disorder (Treatment Resistant Depression)
2.2.1 BrainsWay
2.2.2 Cerbomed/tVNS
2.2.3 CerebralRx
2.2.4 Endonovo Therapeutics/Cervel Neurotech
2.2.5 LivaNova
2.2.6 MagVenture
2.2.7 Neuronetics
2.2.8 Tal Medical
2.3 Neurodegenerative Disorders
2.3.1 Aleva Neurotherapeutics
2.3.2 Bioinduction
2.3.3 Cala Health
2.3.4 Functional Neuromodulation
2.3.5 Neuronix
2.4 Stroke, Spinal Cord Injury and Limb Loss
2.4.1 Bioness
2.4.2 Finetech Medical
2.4.3 Hanger
2.4.4 MicroTransponder
2.4.5 Ottobock
Exhibit 2-1: Current and Emerging Neurostimulation Technologies Targeting Neurological Conditions
3. Product Markets
3.1 Parkinson's/Essential Tremor/Alzheimer's (Deep Brain Stimulation)
3.1.1 Market by Major Geography
3.1.2 Supplier Shares
3.2 Drug-Refractory Epilepsy
3.2.1 Market by Major Geography
3.2.2 Supplier Shares
3.3 Major Depressive Disorder
3.3.1 Market by Major Geography
3.3.2 Supplier Shares
3.4 Post-Stroke Mobility
3.4.1 Market by Major Geography
3.4.2 Supplier Shares
Exhibit 3-1: Global Market for Neurostimulation Technologies Targeting Neurological Disorders by Major Type, Clinical Application and Major Geography, 2018 - 2024
Exhibit 3-2: Global Market for Neurostimulation Technologies Targeting Degenerative Neurological Disorders by Major Type and Major Geography, 2018 - 2024
Exhibit 3-3: U.S. Market for Neurostimulation Technologies Targeting Degenerative Neurological Disorders, 2018 - 2024
Exhibit 3-4: Major Europe Market for Neurostimulation Technologies Targeting Degenerative Neurological Disorders, 2018 - 2024
Exhibit 3-5: Major Asia-Pacific Market for Neurostimulation Technologies Targeting Degenerative Neurological Disorders, 2018 - 2024
Exhibit 3-6: Rest-of-World Market for Neurostimulation Technologies Targeting Degenerative Neurological Disorders, 2018 - 2024
Exhibit 3-7: Neurostimulation Technologies Targeting Degenerative Neurological Disorders, Estimated Global Supplier Shares, 2018
Exhibit 3-8: Global Market for Neurostimulation Technologies Devices Targeting Drug-Refractory Epilepsy by Implant Type and Major Geography, 2018 - 2024
Exhibit 3-9: U.S. Market for Neurostimulation Technologies Devices Targeting Drug-Refractory Epilepsy by Implant Type, 2018 - 2024
Exhibit 3-10: Major Europe Market for Neurostimulation Technologies Devices Targeting Drug-Refractory Epilepsy by Implant Type, 2018 - 2024
Exhibit 3-11: Major Asia-Pacific Market for Neurostimulation Technologies Devices Targeting Drug-Refractory Epilepsy by Implant Type, 2018 - 2024
Exhibit 3-12: Rest-of-World Market for Neurostimulation Technologies Devices Targeting Drug-Refractory Epilepsy by Implant Type, 2018 - 2024
Exhibit 3-13: Estimated Global Supplier Shares of Technologies Targeting Drug-Refractory Epilepsy, 2018
Exhibit 3-14: Global Market for Neurostimulation Technologies Devices Targeting Major Depressive Disorder by Major Type and Major Geography, 2018 - 2024
Exhibit 3-15: U.S. Market for Neurostimulation Technologies Devices Targeting Major Depressive Disorder by Major Type, 2018 - 2024
Exhibit 3-16: Major Europe Market for Neurostimulation Technologies Devices Targeting Major Depressive Disorder by Major Type, 2018 - 2024
Exhibit 3-17: Major Asia-Pacific Market for Neurostimulation Technologies Devices Targeting Major Depressive Disorder by Major Type, 2018 - 2024
Exhibit 3-18: Rest-of-World Market for Neurostimulation Technologies Devices Targeting Major Depressive Disorder by Major Type, 2018 - 2024
Exhibit 3-19: Estimated Global Supplier Shares of Technologies Targeting Major Depressive Disorder, 2018
Exhibit 3-20: Global Market for Neurostimulation Technologies Targeting Post-Stroke Mobility by Technology Type and Major Geography, 2018 - 2024
Exhibit 3-21: U.S. Market for Neurostimulation Technologies Targeting Post-Stroke Mobility by Technology Type, 2018 - 2024
Exhibit 3-22: Major Europe Market for Neurostimulation Technologies Targeting Post-Stroke Mobility by Technology Type, 2018 - 2024
Exhibit 3-23: Major Asia-Pacific Market for Neurostimulation Technologies Targeting Post-Stroke Mobility by Technology Type, 2018 - 2024
Exhibit 3-24: Rest-of-World Market for Neurostimulation Technologies Targeting Post-Stroke Mobility by Technology Type, 2018 - 2024
Exhibit 3-25: Estimated Global Supplier Shares of Technologies Targeting Post-Stroke Mobility, 2018
Ready to get started?
We help you make smarter decisions and form stronger partnerships through curated events, independent market intelligence products and services, and digital-forward media.
